

# Corrigendum: Neferine Ameliorates Sepsis-Induced Myocardial Dysfunction Through Anti-Apoptotic and Antioxidative Effects by Regulating the PI3K/AKT/mTOR Signaling Pathway

Zhen Qi<sup>1†</sup>, Renrong Wang<sup>2†</sup>, Rongheng Liao<sup>1</sup>, Song Xue<sup>1\*</sup> and Yongyi Wang<sup>1\*</sup>

<sup>2</sup>Department of Cardiology, Wuxi No. 2 Hospital, Nanjing Medical University, Wuxi, China

### OPEN ACCESS

#### Edited and reviewed by:

Francesco Rossi, University of Campania Luigi Vanvitelli, Italy

#### \*Correspondence:

Song Xue xuesong64@163.com Yongyi Wang wangyongyi@renji.com

<sup>†</sup>These authors have contributed equally to this work

#### Specialty section:

This article was submitted to Cardiovascular and Smooth Muscle Pharmacology, a section of the journal Frontiers in Pharmacology

> **Received:** 06 April 2022 **Accepted:** 13 April 2022 **Published:** 29 April 2022

#### Citation:

Qi Z, Wang R, Liao R, Xue S and Wang Y (2022) Corrigendum: Neferine Ameliorates Sepsis-Induced Myocardial Dysfunction Through Anti-Apoptotic and Antioxidative Effects by Regulating the PI3K/AKT/mTOR Signaling Pathway. Front. Pharmacol. 13:913778. doi: 10.3389/fphar.2022.913778 Keywords: neferine, apoptosis, oxidative stress, mitochondria, lipopolysaccharide, cardiac dysfunction, sepsis

<sup>1</sup>Department of Cardiovascular Surgery, Renii Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China,

#### A Corrigendum on

## Neferine Ameliorates Sepsis-Induced Myocardial Dysfunction Through Anti-Apoptotic and Antioxidative Effects by Regulating the PI3K/AKT/mTOR Signaling Pathway

by Qi, Z., Wang, R., Liao, R., Xue, S. and Wang, Y. (2021). Front. Pharmacol. 12:706251. doi: 10.3389/ fphar.2021.706251

In the original article, there was a mistake in the caption for **Figure 6C** as published. A clerical error occurred when we prepared the paper. The correct caption appears below.

"(C) Densitometric quantification analysis of the protein expression levels of p-PI3K, PI3K, p-AKT, AKT, p-mTOR, and mTOR in mice."

In the original article, there was a mistake in **Figures 2**, **5**, **6** as published. The image in the "LPS + Nef" group within **Figure 2B**, the image in the "LPS + Nef" group within **Figure 5A**, and the mTOR bands within **Figure 6E**, were uploaded with errors. The corrected **Figures 2**, **5**, **6** appear below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Qi, Wang, Liao, Xue and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.



before LPS injection (15 mg/kg) and then administer of for three consecutive days. The mortality of mice within 72 h was recorded (n = 15 mice). (**B**–I) the mice were treated with neferine (20 mg/kg, intraperitoneally (i.p.) 2 h before LPS challenge (10 mg/kg, i.p.), and cardiac function was examined (n = 6). (**B**) Representative echocardiographic images. (**C**) Heart rate (HR). (**D**) Fractional shortening (FS). (**E**) Ejection fraction (EF). (**F**) Left ventricular internal systolic dimension (LVIDs). (**G**) Left ventricular internal diastolic dimension (LVIDb). (**H**) Left ventricular posterior wall systolic thickness (LVPWs). (**I**) Left ventricular posterior wall diastolic thickness (LVPWd). Data are expressed as mean  $\pm$  standard deviation. \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001; ns: no significant difference.



**FIGURE 5** | Neferine reduced the production of reactive oxygen species (ROS) and prevented mitochondrial dysfunction. (A) DCFH-DA staining was used to evaluate the intracellular ROS level in H9c2 cells. Fluorescence intensity was measured. Scale bar, 50  $\mu$ m. (B) Representative images of JC-1 staining in LPS-induced H9c2 cells. Fluorescence intensity was measured. Scale bar, 50  $\mu$ m. (C-E) Western blot analysis and densitometric quantification of SOD2 and iNOS protein expression in H9c2 cells. (F) SOD1 and iNOS protein expression levels in septic mice were detected by Western blot (n = 6). (G,H) Densitometric quantification of SOD1 and iNOS protein expression levels in H9c2 cells were analyzed. All data are expressed as mean  $\pm$  SD. All experiments were repeated at least three times. \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001; ns: no significant difference; DCFH-DA, 2'-7'dichlorofluorescein diacetate.



**FIGURE 6** Neferine reversed the LPS-induced downregulation of the PI3K/AKT/mTOR signaling pathway *in vivo* and *in vitro*. (A) Representative Western blot images of p-PI3K, PI3K, p-AKT, AKT, p-mTOR, and mTOR in mice. (B–E) Representative Western blot images of p-PI3K, PI3K, p-AKT, AKT, p-mTOR, and mTOR in H9c2 cells. (C) Densitometric quantification analysis of the protein expression levels of p-PI3K, PI3K, p-AKT, AKT, p-mTOR, and mTOR in mice. (D–F) Densitometric quantification analysis of the protein expression levels of p-PI3K, PI3K, p-AKT, AKT, p-mTOR, and mTOR in mice. (D–F) Densitometric quantification analysis of the protein expression levels of p-PI3K, PI3K, p-AKT, AKT, p-mTOR, and mTOR in H9c2 cells. All data are expressed as mean ± standard deviation. All experiments were repeated at least three times. \*p < 0.05, \*\*p < 0.01; ns: no significant difference.